Hypopigmentation is a skin condition, where the skin loses the colour or skin pigments due to a decrease in melanin or melanocyte. The formation of pigmented skins may occur in patches or all over the body. Although hypopigmentation may occur among people of all races, the occurrence of such a condition is more noticeable among individuals with a dark complexion. Market Industry Reports (MIR) has published a new report titled “Hypopigmentation Disorders Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030.” According to the report, the global hypopigmentation disorders treatment market is anticipated to witness a substantial CAGR of 5.6% in the forecast period.
Increasing awareness among patients, technological advancements in the sector of aesthetic treatment of pigmentation related conditions, and the growing geriatric population have been pivotal in dictating the growth of the hypopigmentation disorders treatment market. Moreover, increasing incidences of disorders related to hypopigmentation, namely albinism, and vitiligo is anticipated to be the major driver of the global hypopigmentation disorders treatment market between 2019 and 2030.
Major Key Players of the Hypopigmentation Disorders Treatment Market are:ALLERGAN, SkinCeuticals International, PIERRE FABRE GROUP, Episciences, RXi Pharmaceuticals, Obagi Cosmeceuticals and Alvogen among others
No comments:
Post a Comment